These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

533 related items for PubMed ID: 17908055

  • 21. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
    Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD.
    Vaccine; 2013 Jan 21; 31(5):770-6. PubMed ID: 23228813
    [Abstract] [Full Text] [Related]

  • 22. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N.
    Pediatr Infect Dis J; 2012 May 21; 31(5):494-500. PubMed ID: 22301476
    [Abstract] [Full Text] [Related]

  • 23. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.
    Vermeulen JN, Lange JM, Tyring SK, Peters PH, Nunez M, Poland G, Levin MJ, Freeman C, Chalikonda I, Li J, Smith JG, Caulfield MJ, Stek JE, Chan IS, Vessey R, Schödel FP, Annunziato PW, Schlienger K, Silber JL.
    Vaccine; 2012 Jan 20; 30(5):904-10. PubMed ID: 22154769
    [Abstract] [Full Text] [Related]

  • 24. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector.
    Simon JK, Carter M, Pasetti MF, Sztein MB, Kotloff KL, Weniger BG, Campbell JD, Levine MM.
    Vaccine; 2011 Nov 28; 29(51):9544-50. PubMed ID: 21986218
    [Abstract] [Full Text] [Related]

  • 25. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
    Cools HJ, Gussekloo J, Remmerswaal JE, Remarque EJ, Kroes AC.
    J Med Virol; 2009 May 28; 81(5):908-14. PubMed ID: 19319953
    [Abstract] [Full Text] [Related]

  • 26. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
    Zuccotti G, Amendola A, Viganò A, Pariani E, Zappa A, Pogliani L, Giacomet V, Savarino A, Podestà A, Rottoli A, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2007 Sep 17; 25(37-38):6692-8. PubMed ID: 17697730
    [Abstract] [Full Text] [Related]

  • 27. Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age.
    Tyring SK, Diaz-Mitoma F, Padget LG, Nunez M, Poland G, Cassidy WM, Bundick ND, Li J, Chan IS, Stek JE, Annunziato PW, Protocol 009 Study Group.
    Vaccine; 2007 Feb 26; 25(10):1877-83. PubMed ID: 17227688
    [Abstract] [Full Text] [Related]

  • 28. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.
    Silber JL, Chan IS, Wang WW, Matthews H, Kuter BJ.
    Pediatr Infect Dis J; 2007 Jul 26; 26(7):572-6. PubMed ID: 17596796
    [Abstract] [Full Text] [Related]

  • 29. Response to a monovalent 2009 influenza A (H1N1) vaccine.
    Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL.
    N Engl J Med; 2009 Dec 17; 361(25):2405-13. PubMed ID: 19745216
    [Abstract] [Full Text] [Related]

  • 30. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.
    Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ, Klimov A, Keitel WA, Nichol KL, Carr WW, Treanor JJ, Walter Reed Health Care System Influenza Vaccine Consortium.
    Arch Intern Med; 2008 Dec 08; 168(22):2405-14. PubMed ID: 19064822
    [Abstract] [Full Text] [Related]

  • 31. [Safety and immunogenicity on three lots of influenza split vaccines among adults].
    Zhang ZL, Wang X, Zhu XJ, Zhang Y, Liu Y, Gao ZG, Liang M, Li L, Li JM, Liu RK, Dong XJ, Song GX, Zhang DC, Wang WQ, Han YG, Chen JT.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jun 08; 30(6):583-7. PubMed ID: 19957624
    [Abstract] [Full Text] [Related]

  • 32. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R.
    J Infect Dis; 2011 Jun 15; 203(12):1719-28. PubMed ID: 21606530
    [Abstract] [Full Text] [Related]

  • 33. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children.
    Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM.
    Pediatrics; 2005 Apr 15; 115(4):1039-47. PubMed ID: 15805382
    [Abstract] [Full Text] [Related]

  • 34. Debate on annual influenza vaccination in healthcare workers for the same subtype under the vaccine shortage.
    Song JY, Ha SH, Kee SY, Jeong HW, Cheong HJ, Kim WJ.
    J Clin Virol; 2007 Feb 15; 38(2):149-52. PubMed ID: 17196876
    [Abstract] [Full Text] [Related]

  • 35. Dose sparing with intradermal injection of influenza vaccine.
    Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM.
    N Engl J Med; 2004 Nov 25; 351(22):2295-301. PubMed ID: 15525714
    [Abstract] [Full Text] [Related]

  • 36. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
    Li RC, Fang HH, Li YP, Liu YP, Nong Y, Huang GB.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun 25; 29(6):548-51. PubMed ID: 19040034
    [Abstract] [Full Text] [Related]

  • 37. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults.
    McNeil SA, Noya F, Dionne M, Predy G, Meekison W, Ojah C, Ferro S, Mills EL, Langley JM, Halperin SA.
    Vaccine; 2007 Apr 30; 25(17):3464-74. PubMed ID: 17270320
    [Abstract] [Full Text] [Related]

  • 38. Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years.
    Nabeshima S, Kashiwagi K, Murata M, Kanamoto Y, Furusyo N, Hayashi J.
    J Med Virol; 2007 Mar 30; 79(3):320-5. PubMed ID: 17245715
    [Abstract] [Full Text] [Related]

  • 39. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A, Giraldo A, Castañeda E, Martínez M, de la Hoz F, Rivas F, Depetris A, Svennerholm AM, Sack DA.
    Bull Pan Am Health Organ; 1995 Dec 30; 29(4):312-21. PubMed ID: 8605522
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P.
    Vaccine; 2009 Nov 05; 27(47):6589-94. PubMed ID: 19716456
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.